NASDAQ:BRTX Biorestorative Therapies (BRTX) Stock Price, News & Analysis $0.25 +0.04 (+20.10%) Closing price 05/26/2026 04:00 PM EasternExtended Trading$0.48 +0.23 (+92.95%) As of 07:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biorestorative Therapies Stock (NASDAQ:BRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BRTX alerts:Sign Up Key Stats Today's Range$0.21▼$0.2950-Day Range$0.17▼$0.3352-Week Range$0.16▼$2.05Volume10.68 million shsAverage Volume1.79 million shsMarket Capitalization$6.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment. Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy. Biorestorative Therapies’ candidate has completed early-stage clinical evaluation and is advancing through planned trials to assess safety and efficacy in reducing the duration and severity of oral mucositis. Preclinical studies have also been conducted to explore additional indications, including inflammatory and degenerative conditions. Headquartered in Malvern, Pennsylvania, Biorestorative Therapies manages its research, manufacturing and clinical development activities in the United States. The company works with clinical research organizations and academic centers to support its ongoing trials and maintains a leadership team with experience spanning cell therapy, clinical development and regulatory affairs. Biorestorative Therapies continues to pursue partnerships to expand its pipeline and accelerate the path to potential regulatory approval.AI Generated. May Contain Errors. Read More Biorestorative Therapies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreBRTX MarketRank™: Biorestorative Therapies scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingBiorestorative Therapies has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBiorestorative Therapies has received no research coverage in the past 90 days.Read more about Biorestorative Therapies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biorestorative Therapies are expected to grow in the coming year, from ($0.66) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biorestorative Therapies is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biorestorative Therapies is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiorestorative Therapies has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biorestorative Therapies' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.93% of the float of Biorestorative Therapies has been sold short.Short Interest Ratio / Days to CoverBiorestorative Therapies has a short interest ratio ("days to cover") of 0.55, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biorestorative Therapies has recently decreased by 0.35%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiorestorative Therapies does not currently pay a dividend.Dividend GrowthBiorestorative Therapies does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Biorestorative Therapies this week, compared to 2 articles on an average week.Search Interest3 people have searched for BRTX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Biorestorative Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biorestorative Therapies insiders have not sold or bought any company stock.Percentage Held by Insiders13.60% of the stock of Biorestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.38% of the stock of Biorestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biorestorative Therapies' insider trading history. Receive BRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biorestorative Therapies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BRTX Stock News HeadlinesBioRestorative Therapies, Inc: BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline DataMay 26 at 2:02 PM | finanznachrichten.deBioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline DataMay 26 at 11:00 AM | globenewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 27 at 1:00 AM | Profits Run (Ad)BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticalsMay 13, 2026 | globenewswire.comBioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc DiseaseMay 7, 2026 | globenewswire.comBioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical PlatformApril 30, 2026 | globenewswire.comBioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its ...April 21, 2026 | markets.businessinsider.comBioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical PlatformApril 21, 2026 | globenewswire.comSee More Headlines BRTX Stock Analysis - Frequently Asked Questions How have BRTX shares performed this year? Biorestorative Therapies' stock was trading at $1.1750 at the start of the year. Since then, BRTX stock has decreased by 78.7% and is now trading at $0.2498. How were Biorestorative Therapies' earnings last quarter? Biorestorative Therapies, Inc. (NASDAQ:BRTX) announced its earnings results on Thursday, May, 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.01. The business earned $0.02 million during the quarter, compared to analysts' expectations of $0.31 million. Biorestorative Therapies had a negative net margin of 3,088.27% and a negative trailing twelve-month return on equity of 508.42%. When did Biorestorative Therapies' stock split? Biorestorative Therapies's stock reverse split on Wednesday, October 27th 2021.The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. Is Biorestorative Therapies doing a stock buyback? Biorestorative Therapies' Board of Directors authorized a share repurchase plan on Tuesday, June 17th 2025, which allows the company to repurchase $2,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 15.9% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's management believes its shares are undervalued. How do I buy shares of Biorestorative Therapies? Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biorestorative Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biorestorative Therapies investors own include Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), NVIDIA (NVDA), American Graphite Technologies (AGIN). Company Calendar Last Earnings5/14/2026Today5/27/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BRTX's financial health is in the Red zone, according to TradeSmith. BRTX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealthcare Current SymbolNASDAQ:BRTX Previous SymbolOTCMKTS:BRTX CIK1505497 Webwww.biorestorative.com Phone631-760-8100FaxN/AEmployees7Year Founded1997Profitability EPS (Trailing Twelve Months)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.24 million Net Margins-3,088.27% Pretax Margin-3,088.27% Return on Equity-508.42% Return on Assets-230.94% Debt Debt-to-Equity RatioN/A Current Ratio2.35 Quick Ratio2.35 Sales & Book Value Annual Sales$357.87 thousand Price / Sales17.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book2.08Miscellaneous Outstanding Shares25,478,000Free Float22,013,000Market Cap$6.36 million OptionableNot Optionable Beta0.29 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:BRTX) was last updated on 5/27/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biorestorative Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biorestorative Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
